Product is added to your Wishlist

Global Pharmacogenomics (PGx) Market Analysis: Focus On Ecosystem Players (Diagnostic Test, Pharmaceutical & Others), Therapeutic Applications (Oncology, Cardiovascular & Others), and Geography– Estimation & Forecast 2022

Advancement and innovation of new healthcare technologies such as next generation sequencing, high throughput screening (HTS), and Digital PCR are developing the platform for the growth of Pharmacogenomics (PGx) market. The global PGx market is expected to grow over $14.85 billion by 2022.

SKU: BH007A

Published Year: 2016

Rapid advancement and innovation of new healthcare technologies such as next generation sequencing, High Throughput Screening (HTS), and Digital Polymerase Chain Reaction (PCR) are further enhancing the platform for the growth of Pharmacogenomics (PGx) market. The completion of first human genome project in 1990s has created the platform for the development of further enhanced Pharmacogenomics solutions. PGx is not a modernized market but the increasing demand for precision medicine, targeted therapeutics and increasing cases of adverse drug reactions are some of the major factors which led to a tremendous growth rate in the past few years.

Since the announcement of ‘Precision Medicine Initiative’ by the President Barack Obama in January 2015, a large number of Research and Development (R&D) programs has been taken up for the developing precise drugs, targeted therapeutics, and laboratory tests which required Pharmacogenomics analysis. At present, government initiatives are focused towards launching a large number of PGx test & drugs, controlling the increasing level of genetic disorders, and integrating advanced technologies to fulfill the unmet needs of the patients. Most of the developments taking place in the present scenario are mainly related to oncology & cardiovascular diseases, but it is anticipated that it may target almost all therapeutic areas affected by genetic mutations.

Government regulations and standards are sustaining the growth and development of the PGx market. The main aim of these regulations is to make the PGx solutions more adaptable and focused toward oncology, pain management, CNS, CVD, and infectious diseases among others. The patients are benefitted indirectly by these regulations as it save time and cut-down cost as the patients get the required treatment for the specific disease. The market growth is propelled due to factors such as: rising usage in drug discovery processes, increasing demand for pharmacogenomics & precise drugs, technological innovation and advancement, increasing genetic disorder/abnormalities, and government support and regulations.

This study includes an overview and analysis of the PGx market, by type of ecosystem players ,type of therapeutics application, technology type, and geographical regions; allowing the researcher to develop a comprehensive outlook of the market. The PGx market report presents a detailed analysis of the key market dynamics and provides an extensive insight into various forms of developments, trends and key participants. All of the above mentioned report coverage parameters are discussed across different regions like North America, Europe, Asia Pacific (APAC), and Rest of the World (ROW).

While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, compliances, and regulatory bodies, and their involvement in the PGx market. The research incorporates Porter’s Five Forces Model for in-depth analysis of the PGx market and an assessment of the factors governing the same.

TABLE OF CONTENT
1	Report Overview
1.1	Report Scope
1.1.1	Report Coverage
1.1.2	Assumptions And Limitations
1.1.3	Market Classification & Segmentation
1.2	Research Methodology
1.2.1	Data Points Considered For Market Size Estimation
1.2.2	Key Data Point Sources
1.2.2.1	Key Data Points From Primary Sources
1.2.2.2	Key Data Points From Secondary Sources
1.2.3	Data Triangulation
1.2.4	Top-Down Approach
1.2.5	Bottom-Up Approach
1.3	Report Description
2	Executive Summary
2.1	Global Market Scenario
3	Market Overview
3.1	Introduction
3.2	Pharmacogenomics: Mechanism Of Action
3.3	Role Of Companion Diagnostics In PGX
3.4	Role Of Biomarkers In PGX
3.5	Role Of Molecular Diagnostics In PGX
3.6	Benefits Of PGX
3.7	End-Use Applications Of PGX
3.8	Market Dynamics
3.8.1	Market Drivers
3.8.2	Market Challenges
3.8.3	Market Opportunities
4	Competitive Insights
4.1	Key Market Developments & Strategies
4.1.1	Competitive Landscape Of Some Of The Key Players
4.1.2	Partnerships, Joint Ventures And Collaborations
4.1.2.1	Key Insights
4.1.2.2	Recent Partnerships, Joint Ventures And Collaborations
4.1.3	Product Launch And Developments
4.1.3.1	Key Insights
4.1.3.2	Recent Product Launch And Developments
4.1.4	Patents, Licensing, Certification And Approvals
4.1.4.1	Key Insights
4.1.4.2	Recent Patents, Licensing, Certification And Approvals
4.1.5	Mergers And Acquisitions
4.1.5.1	Key Insights
4.1.5.2	Recent Mergers And Acquisitions
4.1.6	Business Contracts And Business Expansions
4.1.6.1	Key Insights
4.1.6.2	Recent Business Contracts And Business Expansions
4.1.7	Other Strategies
4.1.7.1	Key Insights
4.1.7.2	Recent Developments Of Other Strategies
4.2	Porter’s Five Forces Analysis
4.2.1	Threat Of Substitutes
4.2.2	Threat Of New Entrants
4.2.3	Bargaining Power Of Buyers
4.2.4	Bargaining Power Of Suppliers
4.2.5	Intensity Of Competitive Rivalry
5	Industry Analysis
5.1	Patent Analysis
5.1.1	Some Of The Key Players
5.1.2	Others (University/Hospital/Person)
5.2	Regulations, Consortiums, Certifications, & Standards
5.2.1	Regulatory Bodies
5.2.2	Examples Of Some Common Acts Certifications
5.3	Value Chain Analysis
6	Global Pharmacogenomics Market By Technology
6.1	Market Segmentation By Technology
6.2	Microarray
6.2.1	Introduction
6.2.2	Microarray: Types, Applications & Key Players
6.2.3	Microarray: Market Dynamics & Recent Developments
6.3	Sequencing
6.3.1	Introduction
6.3.2	Sequencing: Market Dynamics, Applications & Key Players
6.3.3	Types Of Sequencing Technologies
6.3.3.1	Sanger Sequencing
6.3.3.2	Pyrosequencing
6.3.3.3	Next-Gen Sequencing (NGS)
6.3.3.3.1	Next-Gen Sequencing (NGS) Applications & Key Players
6.3.3.3.2	Next-Gen Sequencing (NGS) Recent Developments
6.4	Polymerase Chain Reaction (PCR)
6.4.1	Introduction
6.4.2	PCR Types
6.4.3	PCR: Market Dynamics, Applications & Key Players
6.5	Other Technologies
6.5.1	Mass Spectrometry
6.5.2	Electrophoresis
7	Global Pharmacogenomics Market By Ecosystem Players
7.1	PGX Ecosystem Players: Overview
7.2	Market Segmentation By Ecosystem Players
7.2.1	Market Insights & Statistics
7.3	Diagnostic Test Companies
7.3.1	Introduction
7.3.2	Market Statistics
7.3.3	Diagnostic Companies: Drivers & Challenges
7.3.4	Recent Key Developments
7.3.5	Key Players
7.4	Pharmaceuticals Companies
7.4.1	Introduction
7.4.2	Market Statistics
7.4.3	Drug Development Process
7.4.4	Role Of Pharmaceutical Companies & Example Of Some Drugs
7.4.5	Pharmaceuticals Companies: Drivers & Challenges
7.4.6	Recent Key Developments
7.4.7	Key Players
7.5	Service Providers
7.5.1	Introduction
7.5.2	Market Statistics
7.5.3	Service Provider: Roles & Big Data Benefits
7.5.4	Big Data Companies: Drivers & Challenges
7.5.5	Recent Key Developments
7.5.6	Key Players
8	Global Pharmacogenomics Market By Therapeutic Applications
8.1	Market Segmentation
8.2	Market Statistics
8.3	Cancer/Oncology
8.3.1	Key Insights & Statistics
8.3.2	Market Statistics
8.3.3	Types Of Cancer
8.3.4	Cancer: Examples Of Some Drugs
8.3.5	Cancer: Examples Of Some Tests
8.3.6	Market Dynamics & Key Players
8.3.7	Recent Key Developments
8.4	Cardiovascular Diseases (CVD)
8.4.1	Key Insights & Statistics
8.4.2	Market Statistics
8.4.3	CVD: Examples Of Some Drugs
8.4.4	CVD: Examples Of Some Tests
8.4.5	Recent Key Developments & Key Players
8.5	Central Nervous System(CNS)
8.5.1	Key Insights & Statistics
8.5.2	Market Statistics
8.5.3	CNS: Examples Of Some Drugs
8.5.4	CNS: Examples Of Some Tests
8.5.5	Recent Key Developments & Key Players
8.6	Infectious Diseases
8.6.1	Key Insights & Statistics
8.6.2	Market Statistics
8.6.3	Infectious Diseases : Examples Of Some Drugs
8.6.4	Recent Key Developments & Key Players
8.7	Other Diseases
8.7.1	Key Insights & Statistics
8.7.2	Market Statistics
8.7.3	Other Diseases : Examples Of Some Drugs
8.7.4	Other Diseases : Examples Of Some Tests
8.7.5	Recent Key Developments & Key Players
9	Global Pharmacogenomics Market By Geography
9.1	Geographical Scenario
9.2	Market Insights & Statistics
9.3	North America
9.3.1	Market Scope
9.3.2	North America: Market Insights & Statistics
9.3.3	North American Market Dynamics
9.3.4	Key Regulatory Bodies & Associations
9.3.5	The U.S.
9.3.5.1	The U.S.: Market Statistics
9.3.5.2	The U.S.: Key Insights
9.3.6	Canada
9.3.7	Recent Key Developments
9.4	Europe
9.4.1	Market Scope
9.4.2	Europe: Market Insights & Statistics
9.4.3	European Market Dynamics
9.4.4	Key Regulatory Bodies & Associations
9.4.5	The U.K.
9.4.6	Germany
9.4.7	Recent Key Developments
9.5	Asia-Pacific (APAC)
9.5.1	Market Scope
9.5.2	APAC: Market Insights & Statistics
9.5.3	APAC Market Dynamics
9.5.4	China
9.5.5	Japan
9.5.6	India
9.5.7	Recent Key Developments
9.6	Rest Of The World (ROW)
9.6.1	ROW: Market Insights & Statistics
9.6.2	Middle East
9.6.3	South America
9.6.4	Africa
9.6.5	Recent Key Development
10	Company Overview
10.1	Abbott Laboratories
10.1.1	Overview
10.1.2	Financials
10.1.3	Financial Summary
10.1.4	Key Developments
10.1.5	SWOT Analysis
10.2	Affymetrix, Inc.
10.2.1	Overview
10.2.2	Financials
10.2.3	Financial Summary
10.2.4	Key Developments
10.2.5	SWOT Analysis
10.3	Assurex Health, Inc.
10.3.1	Overview
10.3.2	Key Developments
10.3.3	SWOT Analysis
10.4	Astrazeneca
10.4.1	Overview
10.4.2	Financials
10.4.3	Financial Summary
10.4.4	Key Developments
10.4.5	SWOT Analysis
10.5	Illumina, Inc.
10.5.1	Overview
10.5.2	Financials
10.5.3	Financial Summary
10.5.4	Key Developments
10.5.5	SWOT Analysis
10.6	Laboratory Corporation Of America Holdings
10.6.1	Overview
10.6.2	Financials & Financial Summary
10.6.3	Key Developments
10.6.4	SWOT Analysis
10.7	Myriad Genetics, Inc.
10.7.1	Overview
10.7.2	Financials & Financial Summary
10.7.3	Key Developments
10.7.4	SWOT Analysis
10.8	Pfizer, Inc.
10.8.1	Overview
10.8.2	Financials
10.8.3	Financial Summary
10.8.4	Key Developments
10.8.5	SWOT Analysis
10.9	Qiagen, Inc.
10.9.1	Overview
10.9.2	Financials
10.9.3	Financial Summary
10.9.4	Key Developments
10.9.5	SWOT Analysis
10.10	Roche Holding AG-BR
10.10.1	Overview
10.10.2	Financials
10.10.3	Financial Summary
10.10.4	Key Developments
10.10.5	SWOT Analysis
10.11	TEVA Pharmaceutical Industries Ltd.
10.11.1	Overview
10.11.2	Financials
10.11.3	Financial Summary
10.11.4	Key Developments
10.11.5	SWOT Analysis
10.12	Thermo Fisher Scientific
10.12.1	Overview
10.12.2	Financials
10.12.3	Financial Summary
10.12.4	Key Developments
10.12.5	SWOT Analysis
10.13	Transgenomic, Inc.
10.13.1	Overview
10.13.2	Financials & Financial Summary
10.13.3	Key Developments
10.13.4	SWOT Analysis
10.14	Other Emerging Companies
10.14.1	Diagnostic Test Companies
10.14.1.1	Companiondx Reference Lab, LLC
10.14.1.2	Mapmy Genome
10.14.1.3	Asuragen
10.14.1.4	23andme
10.14.1.5	Cnsdose
10.14.2	Pharmaceutical Companies
10.14.2.1	Actinium Pharmaceuticals, Inc
10.14.2.2	Foundation Medicine
10.14.3	Service Providers
10.14.3.1	PGX Software LLC
10.14.3.2	Gene Logic
10.14.3.3	Genewiz
10.14.3.4	Conatus Consulting, LLC
10.14.4	Care Providers
10.14.4.1	Gene DX
10.14.4.2	Mayo Clinic
11	List Of Acronyms
List Of Figures
1	Year Consideration
2	Market Classification & Segmentation
3	Research Methodology
4	Global Pharmacogenomics Market ($Billion)
5	Global Pharmacogenomics Market Value, 2015-2022 ($Billion)
6	Global PGX Market, By Ecosystem, 2015-2022 ($Billion)
7	Global PGX Market Share, By Therapeutic Application, 2015-2022 ($Billion)
8	Global Pharmacogenomics Market, By Geography-2022
9	Mechanism Of Action
10	Role Of Companion Diagnostics In PGX
11	Role Of Biomakers In PGX
12	Role Of Molecular Diagnostics IN PGX
13	Benefits Of PGX
14	End-Use Applications Of PGX
15	Market Dynamics
16	Partnerships, Joint Ventures And Collaborations: Key Players Analysis
17	Product Launch And Developments: Key Players Analysis
18	Patents, Licensing, Certification And Approvals : Key Players Analysis
19	Mergers And Acquisitions: Key Players Analysis
20	Business Contracts And Business Expansions : Key Players Analysis
21	Others Strategies: Key Players Analysis
22	Porter’s Five Forces Analysis
23	Threat Of Substitutes
24	Threat Of New Entrants
25	Bargaining Power Of Buyers
26	Bargaining Power Of Suppliers
27	Intensity Of Competitive Rivalry
28	Roles And Responsibilities Of Healthcare Policy Makers
29	Role Of FDA In PGX
30	Classification Of Medical Devices
31	Examples Of Some Common Acts
32	Example Of Some Certifications
33	Value Chain Analysis
34	Example Of Some Significant Players In PGX Value Chain
35	Generalized Process For The Microarray
36	Different Types Of Microarrays
37	Applications Of Microarrays
38	Microarray- Drivers & Challenges
39	Sequencing Technologies In PGX
40	Sequencing - Drivers & Challenges
41	Applications Of Sequencing
42	NGS- Drivers & Challenges
43	Applications Of NGS
44	Generalized Process For PCR
45	Different Types Of PCR
46	PCR - Drivers & Challenges
47	Applications Of PCR
48	Applications Of Mass Spectrometry
49	Applications Of Electrophoresis
50	Overview Of PGX Ecosystem Players
51	Global PGX Market By Ecosystem Players
52	Global Pharmacogenomics Market, By Ecosystem , 2015-2022 ($Billion)
53	Global PGX Ecosystem Market, By Diagnostic Tests Companies, 2015-2022 ($Billion)
54	Global PGX Diagnostic Tests Market, By Therapeutic Applications, 2015-2022 ($Billion)
55	Global PGX Diagnostic Tests Market, By Geography, 2015-2022 ($Billion)
56	Diagnostic Companies- Drivers & Challenges
57	Global PGX Ecosystem Market, By Pharmaceutical Companies, 2015-2022 ($Billion)
58	Global PGX Pharmaceutical Market, By Therapeutic Applications, 2015-2022 ($Billion)
59	Global PGX Pharmaceutical Market, By Geography, 2015-2022 ($Billion)
60	Drug Development Process
61	Role Of Pharmaceuticals Companies
62	Pharmaceuticals Companies- Drivers & Challenges
63	Global PGX Ecosystem Market, By Service Providers, 2015-2022 ($Billion)
64	Global PGX Service Providers Market, By Therapeutic Applications, 2015-2022 ($Billion)
65	Global PGX Service Providers Market, By Geography, 2015-2022 ($Billion)
66	Three Data Drivers Of PGX Market
67	Benefits Of Big Data
68	Big Data Companies- Drivers & Challenges
69	Global PGX Market By Therapeutics Applications
70	Global PGX Market, By Theraeutics Application, 2015-2022 ($Billion)
71	Global PGX Market By Oncology,2015-2022($Billion)
72	Global PGX Oncology Market, By Ecosystem, 2015-2022 ($Billion)
73	Global PGX Oncology Market, By Geography, 2015-2022 ($Billion)
74	Types Of Cancer
75	Oncology Market Dynamics
76	Global PGX Market By CVD, 2015-2022 ($Billion)
77	Global PGX CVD Market, By Ecosystem, 2015-2022 ($Billion)
78	Global PGX CVD Market, By Geography, 2015-2022 ($Billion)
79	Global PGX Market By CNS, 2015-2022 ($Billion)
80	Global PGX CNS Market, By Ecosystem, 2015-2022 ($Billion)
81	Global PGX CNS Market, By Geography, 2015-2022 ($Billion)
82	Global PGX Market By Infectious Diseases, 2015-2022 ($Billion)
83	Global PGX Infectious Diseases Market, By Ecosystem, 2015-2022 ($Billion)
84	Global PGX Infectious Diseases Market, By Geography, 2015-2022 ($Billion)
85	Global PGX Market By Other Diseases, 2015-2022 ($Billion)
86	Global PGX Other Diseases Market, By Ecosystem, 2015-2022 ($Billion)
87	Global PGX Other Diseases Market, By Geography, 2015-2022 ($Billion)
88	Growth Trajectory Of PGX Market
89	Global Pharmacogenomics Market, By Geography , 2015-2022 ($Billion)
90	Global Pharmacogenomics Market, By Geography (2015)
91	North American PGX Market, 2015
92	North American PGX Market, 2015-2022 ($Billion)
93	North American Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
94	North American Pharmacogenomics Market, By Ecosystem, 2015-2022 ($Billion)
95	North American Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion)
96	North American Market Dynamics
97	Key Regulatory Bodies & Associations
98	The U.S. PGX Market, 2015-2022 ($Billion)
99	The U.S. Pharmacogenomics Market, By Ecosystem, 2015-2022 ($Billion)
100	The U.S. Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion)
101	Canada PGX Market Dynamics
102	European PGX Market, 2015
103	European PGX Market,2015-2022($Billion)
104	European Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
105	European Pharmacogenomics Market, By Ecosystem, 2015-2022 ($Billion)
106	European Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion)
107	European Market Dynamics
108	Key Regulatory Bodies & Associations
109	The U.K. PGX Market, 2015-2022 ($Billion)
110	The Germany PGX Market, 2015-2022 ($Billion)
111	APAC Country-Wise CAGR Of PGX Market
112	APAC PGX Market, 2015-2022 ($Billion)
113	APAC Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
114	APAC Pharmacogenomics MARKET,BY Ecosystem, 2015-2022 ($Billion)
115	APAC Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion)
116	APAC Market Dynamics
117	The China PGX Market, 2015-2022 ($Billion)
118	China Market Dynamics
119	The Japan PGX Market, 2015-2022 ($Billion)
120	The Indian PGX Market, 2015-2022 ($Billion)
121	Indian Market Dynamics
122	Region-Wise CAGR Of PGX Market
123	ROW PGX Market, 2015-2022 ($Billion)
124	ROW PGX Market, By Sub-Region, 2015-2022 ($Billion)
125	ROW PGX Market, By Ecosystem, 2015-2022 ($Billion)
126	ROW PGX Market, By Therapeutics, 2015-2022 ($Billion)
127	Middle East PGX Market, 2015-2022 ($Billion)
128	South American PGX Market, 2015-2022 ($Billion)
129	African PGX Market, 2015-2022 ($Billion)
130	: Abbott Laboratories, Inc.– Overall Financials, 2013-2015 ($Billion)
131	Abbott Laboratories, Inc.- Financials By Business Segments, 2013-2015 ($Billion)
132	Abbott Laboratories, Inc.– Financials By Geography, 2013-2015 ($Billion)
133	Abbott Laboratories, Inc.- SWOT Analysis
134	Affymetrix, Inc.– Overall Financials, 2013-2015 ($Million)
135	Affymetrix, Inc.- Financials By Business Segments, 2013-2015 ($Million)
136	Affymetrix, Inc.– Financials By Geography,2013-2015 ($Million)
137	Affymetrix, Inc.- SWOT Analysis
138	Assurex Health, Inc.- SWOT Analysis
139	Astrazeneca – Overall Financials, 2013-2015 ($Billion)
140	Astrazeneca- Financials By Business Segments, 2013-2015 ($Billion)
141	Astrazeneca– Financials By Geography,2013-2015 ($Billion)
142	Astrazeneca- SWOT Analysis
143	Illumina, Inc.– Overall Financials, 2013-2015 ($Million)
144	Illumina, Inc.- Financials By Business Segments, 2013-2015 ($Million)
145	Illumina, Inc.– Financials By Geography, 2013-2015 ($Million)
146	Illumina, Inc.- SWOT Analysis
147	Laboratory Corporation Of America Holding.- Overall Financials, 2013-2015 ($Million)
148	Laboratory Corporation Of America Holding—Financials By Business Segments, 2013-2015 ($ Million)
149	Laboratory Corporation Of America Holding.- SWOT analysis
150	Myriad Genetics, Inc.– Overall Financials, 2013-2015 ($Million)
151	Myriad Genetics, Inc.– Financials By Business Segments, 2013-2015 ($Million)
152	Myriad Genetics,INC.- SWOT Analysis
153	Pfizer, Inc.– Overall Financials, 2013-2015 ($Billion)
154	Pfizer,Inc. – Financials By Geography ,2013-2015 ($Billion)
155	Pfizer, Inc.- Financials By Business Segments, 2014-2015 ($Billion)
156	Pfizer, Inc.– Financials By Business Segment, 2013
157	Pfizer, Inc.- SWOT analysis
158	Qiagen– Overall Financials, 2013-2015 ($Million)
159	Qiagen- Financials By Business Segments, 2013-2015 ($Million)
160	Qiagen– Financials By Geography, 2013-2015 ($Million)
161	Qiagen- SWOT Analysis
162	Roche Holding– Overall Financials,2013-2015 ($Billion)
163	Roche Holding- Financials By Business Segments, 2013-2015 ($Billion)
164	Roche Holding– Financials Of Diagnostics Division By Geography, 2013-2015 ($Billion)
165	Roche Holding– Financials Of Pharmaceuticals,SEGMENT By Geography, 2013-2015 ($Billion)
166	Roche Holding- SWOT Analysis
167	TEVA Pharmaceutical Ltd.– Overall Financials, 2013-2015 ($Billion)
168	TEVA Pharmaceutical Ltd.- Financials By Business Segments, 2013-2015 ($Billion)
169	TEVA Pharmaceutical Ltd.– Financials By Geography, 2013-2015 ($Billion)
170	TEVA Pharmaceutical Industries Ltd.- SWOT analysis
171	Thermo Fisher, Inc.- Overall Financials, 2013-2015 ($Billion)
172	Thermo Fisher, Inc.— Financials By Business Segments, 2013-2015 ($Billion)
173	Thermo Fisher, Inc.— Financials By Geography, 2013-2015 ($Billion)
174	Thermo Fisher Scientific, Inc.- SWOT Analysis
175	Transgenomic, Inc.- Overall Financials,2013-2015 ($Million)
176	Transgenomic, Inc.- Financials By Business SEGEMENTS, 2013-2015 ($Million)
177	Transgenomic, Inc.- SWOT Analysis
List of Tables
1	Competitive Landscape: Some Of The Key Players
2	Recent Partnerships, Joint Ventures And Collaborations
3	Recent Product Launch And Developments
4	Recent Patents, Licensing, Certification And Approvals
5	Recent Mergers And Acquisitions
6	Recent Business Contracts And Business Expansions
7	Recent Developments Of Other Strategies
8	Patent Analysis Of Some Key Players
9	Patent Analysis Of Some University/Hospital/Person
10	Microarray- Recent Key Developments
11	NGS- Recent Key Developments
12	Difference Between Realt Time & Digital PCR
13	Diagnostic Test Companies- Recent Key Developments
14	Example Of Some Pharmacogenomic Drugs
15	Pharmaceuticals Companies- Recent Key Developments
16	Service Providers- Recent Key Developments
17	Cancer- Examples Of Some Drugs
18	Cancer- Examples Of Some Tests
19	Oncology- Recent Key Developments
20	CVD- Examples Of Some Drugs
21	CVD- Examples Of Some Tests
22	CNS- Examples Of Some Drugs
23	CNS- Examples Of Some Tests
24	Infectious Diseases- Examples Of Some Drugs
25	Other Diseases- Examples Of Some Drugs
26	North American Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
27	North American Pharmacogenomics Market Recent Key Dvelopments
28	European Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
29	European PGX Market Recent Key Developments
30	APAC Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion)
31	APAC Pharmacogenomics Market Recent Key Developments
32	ROW Pharmacogenomics Market,By Sub-Region, 2015-2022
33	ROW Recent Key Development
34	Abbott Laboratories, Inc. Recent Developments
35	Affymetrix, Inc. Recent Developments
36	Assurex Health, Inc. Recent Developments
37	Astrazeneca Recent Developments
38	Illumina, Inc. Recent Developments
39	Laboratory Corporation Of America Holding Recent Developments
40	Myriad Genetics Recent Developments
41	Pfizer, Inc. Recent Developments
42	Qiagen Recent Developments
43	Roche Holding Recent Developments
44	TEVA Pharmaceutical Industries Ltd. Recent Developments
45	Thermo Fisher, Inc. Recent Developments
46	Transgenomic, Inc. Recent Developments

The global Pharmacogenomics (PGx) market growth is gradually gaining speed as large number of government initiatives and research & development programs have been launched in the last few years.Advancement and innovation of new healthcare technologies such as next generation sequencing, high throughput screening (HTS), and Digital PCR are developing the platform for the growth of Pharmacogenomics (PGx) market. The global PGx market is expected to grow over $14.85 billion by 2022.

The market growth is propelled due to factors such as: rising usage in drug discovery processes, increasing demand for pharmacogenomics & precise drugs, technological innovation and advancement, increasing genetic disorders/abnormalities, and government support and regulations.The report has been further classified on the basis of ecosystem players, therapeutic applications, and geographical regions. Ecosystem is further segmented into: Pharmaceuticals companies, Diagnostic Companies, and Service Providers which includes Software & Healthcare database providers, Hospitals & Care Providers and Insurance Providers.

Diagnostic Test segment is holding the maximum market share and is expected to grow at 11.63% CAGR from 2016 to 2022. This is due to the increasing demand for diagnostic tests as patients are emphasizing more on pre-diagnosis treatment, increasing genetic disorders & mutational diseases, and government initiatives and investment in research and development programs among others.

In North America, existing players are integrating with new start-ups through partnerships and collaboration to capture the North American segment. North American local players are entering in other developing regions to capture more market share. Throughout the Asia-Pacific and European countries, regulatory bodies are rolling out regulations to keep a check on latest technologies.

North America is the largest contributor in the revenue generation in PGx market followed by Europe region, and is expected to grow at a high CAGR of 12.14% CAGR from 2016 to 2022. APAC region is expected to show the fastest growth globally, and is expected to grow at 18.74% CAGR from 2016 to 2022.

The APAC region is focusing more on technological development and introduction of new gene sequencing and gene mapping tools into healthcare systems to develop specific laboratory diagnostic tests.

We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.

With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.

Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.